| 영문 | receptor | 한글 | 수용체 |
|---|---|---|---|
| 설명 | 세포질내 또는 세포표면에 존재하는 분자구조로서 특이물질과 선택적으로 결합하며 결합에 의해 특이한 생리적 작용을 나타낸다. 펩티드호르몬, 신경전달물질, 항원, 보체, 면역글로불린에 대한 세포표면 수용체와 스테로이드에 대한 세포질내 수용체가 있다. |
||
| 영문 | intermittent positive pressure breathing(IPPB) | 한글 | 간헐적양압호흡 |
|---|---|---|---|
| 설명 | 폐를 팽창시키기 위하여 대기압보다 높은 압력을 이용하는 인공호흡법이다. 신생아 무기폐의 치료나 만성 폐쇄성 호흡기 질환의 급성 악화시, 진단을 위한 가래의 배출을 위하여, 또는 약제의 흡입에 사용하고 있다. 합병증으로 공기가슴증이나 심박출량의 감소가 올 수 있다. |
||
| 영문 | pulse pressure | 한글 | 맥박압 |
|---|---|---|---|
| 설명 | 수축기 혈압과 확장기 혈압의 차이. mmHg로 표시한다. 심장의 수축력, 동맥 내 혈류량, 동맥벽의 긴장도에 영향을 받는다. 정상치는 수축기 혈압의 1/3, 또는 확장기 혈압의 1/2이다. 60mmHg이상을 대맥이라고 하며, 대동맥판막 폐쇄부족증, 갑상샘항진증, 동맥경화증, 혈압이 상승할 때 심장비대, 고열 등에서 볼 수 있다. 20mmHg 이하를 소맥이라고 하며, 급성 심근경색에 의한 좌심실 수축력 저하, 대동맥판막 협착등에서 볼 수 있다. 한편 맥압의 1/3에 확장기 혈압을 더한 것을 평균혈압이라고 한다. |
||
| 영문 | osmotic pressure | 한글 | 삼투압 |
|---|---|---|---|
| 설명 | 삼투라는 현상은 일정 크기 이하의 물질은 통과시키고 그 이상의 크기를 가진 물질은 통과 시키지 못하게 하는 막(반투막)을 사이에 두고 양쪽에 그 막을 투과하지 못하는 물질의 농도가 차이가 날 때 발생하는 것으로 막을 통과할 수 있는 물질이 막 양쪽의 통과 할 수 없는 물질의 농도를 같게 하는 방향으로 움직이는 것을 말한다. |
||
| 영문 | systolic pressure | 한글 | 수축기압 |
|---|---|---|---|
| 설명 | 심활동력, 동맥벽의 탄력성, 혈액량, 혈액의 점성 등에 의하여 결정되는 혈액의 동맥벽에 미치는 압력으로서, 최고혈압은 왼심실로부터 박출이 끝나기 직전에 생기는 압을 말하고 최대 혈압 또는 수축기혈압이라 부른다. 최소혈압은 왼심실의 확장이 끝나는 시기에 생기는 혈압을 말하며 최소혈압 또는 확장기혈압이라고 부른다. 평균혈압은 동맥내압의 평균치를 말하며, 기초혈압은 절대안정 상태에서 측정한 혈압을 말한다. |
||
| ER | efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re... |
|---|---|
| RAR | rapidly adapting receptor; rat insulin receptor; retinoic acid receptor; right arm reclining; right ... |
| MAP | malignant atrophic papulosis; mandibular angle plane; maturation-activated protein; maximal aerobic ... |
| PP | diphosphate group; emphysema [pink puffers]; near point of accommodation [Lat. punctum proximum]; pa... |
| BP | Bachelor of Pharmacy; back pressure; barometric pressure; basic protein; bathroom privileges; bed pa... |
| PCO2 | pressure , carbon dioxide pressure |
|---|---|
| CRLR | Calcitonin Receptor-Like Receptor |
| EGF-receptor | Epidermal Growth Factor receptor |
| IRR | Insulin receptor- related receptor |
| alpha 2MR/LRP | alpha (2)-macroglobulin receptor/low density lipoprotein receptor-related protein |
pressure necrosis
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
|---|---|
| amino acid receptor | <biochemistry> Ligand gated ion channels with specific receptors for amino acid transmitters. An extended protein superfamily that also includes subunits of the nicotinic acetylcholine receptor. (18 Nov 1997) |
| AMPA receptor | <cell biology> Glutamate operated ion channel. See: excitatory amino acid receptor channels. (05 Feb 1998) |
| ANP receptor | <molecular biology> Family of 3 receptors for atrial natriuretic peptide. ANP A and ANP B have intracellular guanylate cyclase and protein kinase like domains. ANP C, shares the extracellular ligand binding and transmembrane domains, but lacks the functional intracellular domains and is not thought to be involved in signal transduction. (18 Nov 1997) |
| asialoglycoprotein receptor | A surface receptor found in hepatocytes that binds galactose-terminal glycoproteins; thus, this receptor removes those proteins from circulation and they are in turn acted upon by hepatocyte lysosomes. (05 Mar 2000) |
| auditory receptor cells | Columnar cell's in the epithelium of the organ of Corti, having hairs (stereocilia) on their apical ends. See: Corti's cells. (05 Mar 2000) |
| beta-adrenergic receptor blocking agent | A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable. Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker. (05 Mar 2000) |
| beta-adrenergic receptor kinase | <enzyme> Cyclic-AMP protein kinase which specifically phosphorylates the agonist-occupied form of beta-adrenergic receptor Registry number: EC 2.7.1.- Synonym: beta-ar kinase, beta-adrenergic receptor kinase 1, g-protein-coupled receptor kinase 2, grk2 (kinase), beta-adrenergic receptor kinase 2, beta-ar kinase 2 (26 Jun 1999) |
| cAMP receptor protein | catabolite (gene) activator protein |
| GABA receptor | <physiology> Ligand gated chloride ion channel forming receptor opened by gamma aminobutyric acid. Two distinct types: A and B. A receptor: One of a family of neurotransmitter receptors with fast intrinsic ion channels that includes the glycine receptor and the nicotinic acetylcholine receptor. Distinct from another major receptor family, the muscarininc acetylcholine receptor and rhodopsin, with no intrinsic ion channel. The A receptor is specifically blocked by bicuculline. It consists of two pairs of protein chains forming an A2B2 complex, the A chains bind benzodiazepine and the B chains bind GABA. The 4 subunits are thought to form a tight group with the chloride channel in the middle. There is considerable similarity between the amino acid sequences of the receptor subunits and those of the nicotinic acetylcholine receptor suggesting that both receptors are derived from some evolutionary ancestor. See: amino acid receptor superfamily. B receptor: Brain receptor (80 kD) for the inhibitory neurotransmitter gamma amino butyric acid. Differs from the A receptor both in agonist specificity (baclofen is a specific agonist) and its effects on cells. It modulates intracellular calcium levels through a Go mediated effect on N type calcium channels and also lowers intracellular cAMP levels by an effect on adenylyl cyclase, thereby reducing the secretion of catecholamines. (05 Jan 1998) |
| p60 tumour necrosis factor receptor-associated kinase | <enzyme> Interacts with and causes phosphorylation of the cytoplasmic domain of the tnf receptor Registry number: EC 2.7.10.- Synonym: p60 tnf receptor-associated kinase, p60-trak (26 Jun 1999) |
| gamma aminobutyric acid receptor | <physiology> Ligand gated chloride ion channel forming receptor opened by gamma aminobutyric acid. Two distinct types: A and B. A receptor: One of a family of neurotransmitter receptors with fast intrinsic ion channels that includes the glycine receptor and the nicotinic acetylcholine receptor. Distinct from another major receptor family, the muscarininc acetylcholine receptor and rhodopsin, with no intrinsic ion channel. The A receptor is specifically blocked by bicuculline. It consists of two pairs of protein chains forming an A2B2 complex, the A chains bind benzodiazepine and the B chains bind GABA. The 4 subunits are thought to form a tight group with the chloride channel in the middle. There is considerable similarity between the amino acid sequences of the receptor subunits and those of the nicotinic acetylcholine receptor suggesting that both receptors are derived from some evolutionary ancestor. See: amino acid receptor superfamily. B receptor: Brain receptor (80 kD) for the inhibitory neurotransmitter gamma amino butyric acid. Differs from the A receptor both in agonist specificity (baclofen is a specific agonist) and its effects on cells. It modulates intracellular calcium levels through a Go mediated effect on N type calcium channels and also lowers intracellular cAMP levels by an effect on adenylyl cyclase, thereby reducing the secretion of catecholamines. (05 Jan 1998) |
| GAP-1 receptor tyrosine kinase | <enzyme> Similar to rasGTPase-activating proteins; inhibits signaling activity of let-60; amino acid sequence given in first source Registry number: EC 2.7.1.- Synonym: gap-1 gene product, gap-1 protein (26 Jun 1999) |
| gene rearrangement, alpha-chain T-cell antigen receptor | Ordered rearrangement of T-cell variable gene regions coding for the alpha-chain of antigen receptors. (12 Dec 1998) |
| gene rearrangement, beta-chain T-cell antigen receptor | Ordered rearrangement of T-cell variable gene regions coding for the beta-chain of antigen receptors. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|